Impact ledger
Editas Medicine, Inc. (EDIT): the developments shaping its investment case
Follow the evidence affecting Editas Medicine, Inc.. Review the key developments below. Continue in Market Ontology to test your assumptions, examine related opportunities, and save the investment case you want to track.
Research Editas Medicine, Inc. · $399/mo
Test assumptions, examine opportunities, and save your research.
Material developments
2026-09-09 · 2 reports
CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump
Channel: Indirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space.
Bullish· 3-12m
2026-09-09
CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M
Channel: Positive sentiment spillover for gene editing technology and platform validation
Bullish· 3-12m
2026-09-25
Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants
Channel: Indirect positive sentiment for the broader synthetic biology and gene editing sector, potential for increased investor interest in platform technologies.
Bullish· 3-12m
Event impact log
9 events mapped to EDIT since 2026-09-09. Evidence through 2026-09-29.
| Date | Event | Channel | Direction | Horizon | Impact |
|---|---|---|---|---|---|
| 2026-09-29 | Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million | Indirect sentiment spillover for gene editing and cell therapy companies. IOVA's commercial success could be seen as a positive signal for the broader advanced therapy market. | watch | 3-12m | 0.20 |
| 2026-09-25 | Ginkgo Bioworks Inks $31M Contract with SaponiQx for AI Vaccine Adjuvants | Indirect positive sentiment for the broader synthetic biology and gene editing sector, potential for increased investor interest in platform technologies. | Bullish | 3-12m | 0.30 |
| 2026-09-12 | Cellectis Schedules September 14 Business Update on Gene Editing and CAR T Pipeline | Second-order effect: Investor sentiment and competitive landscape in the gene editing and CAR T space. Positive or negative news from Cellectis could spill over to peers. | mixed | 1-3m | 0.30 |
| 2026-09-12 | Cellectis Schedules September 14 Business and CAR T Pipeline Update | Second-order effect through sector sentiment. Cellectis's update on gene editing and CAR T development could influence investor perception of the broader gene editing and cell therapy space. | watch | 1-5d | 0.30 |
| 2026-09-12 | Cellectis sets September 14 business update on CAR-T and gene editing pipeline | Indirect sector sentiment; Cellectis's gene editing updates could influence broader investor sentiment towards gene editing technologies. | watch | 1-5d | 0.20 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Pediatric Label After 78% QoQ Sales Jump | Indirect positive sentiment for gene editing technology and platform validation. Potential for increased investor interest in the broader gene editing space. | Bullish | 3-12m | 0.40 |
| 2026-09-09 | CRISPR Therapeutics Expands Casgevy Label to Pediatric Patients as Q2 Sales Hit $76M | Positive read-through for the broader CRISPR gene editing platform and validation of the technology's commercial viability. | Bullish | 3-12m | 0.30 |
| 2026-09-09 | FDA Approves Label Expansion for CRISPR Therapeutics Gene Therapy Casgevy | Positive sentiment spillover for CRISPR-based gene editing companies, potentially increasing investor confidence in the technology platform. | Bullish | 1-3m | 0.30 |
| 2026-09-09 | CRISPR Therapeutics reports 78 percent QoQ Casgevy sales growth to $76M | Positive sentiment spillover for gene editing technology and platform validation | Bullish | 3-12m | 0.40 |
Continue this research
Build your Editas Medicine, Inc. investment case. Continue from the evidence above, change the assumptions the developments move, and save the work to revisit as the case develops.
This ledger is regenerated from Market Ontology's public event pipeline. View the EDIT entity page →